APOE ε4 对患有勒维体痴呆症的临床特征和神经病理学的相关影响
Rong Ye1,2, Anna E Goodheart1,2, Joseph J Locascio1,2
1Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 11, 2025
概括
阿波脂蛋白E (APOE) ε4影响患有勒维体 (DLB) 痴呆症的临床特征和病理学. APOE ε4增加了幻觉,但减少了与勒维体和阿尔茨海默病病理学相关的认知波动.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 神经病理学神经病理学
背景情况:
- 脂蛋白E (APOE) ε4是已知的阿尔茨海默病 (AD) 风险因素.
- 它在患有勒维体痴呆症 (DLB) 的临床表现和病理学中的作用不太清楚.
研究的目的:
- 研究APOE ε4与DLB中核心临床特征和神经病理学的关联.
- 探索APOE基因型对DLB症状表现和潜在病理学的影响.
主要方法:
- 使用了国家阿尔茨海默症协调中心数据集.
- 分析了与DLB特征相关的APOE ε4载体状态,剂量和遗传风险得分.
- 检查了神经病理相关物,包括勒维体和AD病理.
主要成果:
- 携带APOE ε4的患者的认知能力波动和帕金森症的几率降低,但视觉幻觉的几率增加.
- APOE ε4与更严重的新皮质勒维体病理有关,部分由AD共同病理介导.
- 视觉幻觉与勒维体和AD病理相关,而波动性认知主要与勒维体病理阶段有关.
结论:
- DLB的核心临床特征受到APOE单元型的显著影响.
- 了解APOE在DLB病变发生中的作用,可能会为治疗提供新的点.
更多相关视频
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.1K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.6K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Dementia
517
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
517
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
